Medinet CoTSE:2370 41 Gross Margin % is 40.22% as of Mar. 2026, which is 35% above its 10-year median of 29.76. GuruFocus rates TSE:2370 with a GF Score™ of 41/100 and a GF Value™ of 円41.74 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 732 Biotechnology companies, Medinet Co ranks worse than 83.61% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Medinet Co's Gross Profit for the
three
months ended in Mar. 2026 was 円93.7 Mil. Medinet Co's Revenue for the
three
months ended in Mar. 2026 was 円232.9 Mil. Therefore, Medinet Co's Gross Margin % for the quarter that ended in Mar. 2026 was 40.22%.
Warning Sign:
Medinet Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -18.4%.
The historical rank and industry rank for Medinet Co's Gross Margin % or its related term are showing as below:
TSE:2370'
s Gross Margin % Range Over the Past 10 Years
Min: 13.54 Med: 29.76 Max: 45.14
Current: 20.41
During the past 13 years, the highestGross Margin % of Medinet Co was 45.14%. The lowest was 13.54%. And the median was 29.76%.
TSE:2370's Gross Margin % is ranked worse than 83.61% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs TSE:2370: 20.41
Medinet Co had a gross margin of 40.22% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Medinet Co was -18.40% per year.
Medinet Co (TSE:2370) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medinet Co had a gross margin of 40.22% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Medinet Co Gross Margin % Related Terms
Medinet Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Medinet Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2370 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Medinet Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinet Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medinet Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Medinet Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medinet Co (TSE:2370) has a Gross Margin % of 40.22% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Medinet Co and its competitors. This is 35% above median its historical median of 29.76. Over the past decade, Medinet Co's Gross Margin % has ranged from 13.54 to 45.14. According to the industry distribution chart, Medinet Co ranks #612 out of 732 companies in the Biotechnology industry, placing it in the top 83.6%.
Is Medinet Co's Gross Margin % too high?
Medinet Co's current Gross Margin % of 40.22% is 35% above median its 10-year median of 29.76. Over the past 10 years, this metric has ranged from a low of 13.54 to a high of 45.14. The Biotechnology industry median Gross Margin % is 60.91. Medinet Co's value of 40.22% is 34% below this industry median. Based on the distribution chart, Medinet Co ranks #612 out of 732 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medinet Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medinet Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medinet Co ranks #612 out of 732 companies for Gross Margin %. This places Medinet Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Medinet Co's value of 40.22% is 34% below this benchmark. Historically, Medinet Co's own Gross Margin % has ranged from 13.54 to 45.14 over the past decade. While the company's 10-year median is 29.76 vs. the industry median of 60.91, Medinet Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinet Co's current Gross Margin % of 40.22% is 34% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Medinet Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinet Co's current Gross Margin % is 40.22%, which is 35% above median its own 10-year median of 29.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinet Co stock overvalued right now?
Based on GuruFocus' analysis, Medinet Co (TSE:2370) is currently considered Possible Value Trap. The stock's GF Value™ is 円41.74, compared to a current price of 円25.00 — trading 40.1% below its estimated fair value. The current Gross Margin % is 40.22%, which is 35% above median its 10-year median of 29.76 and 34% below the Biotechnology industry median of 60.91. Medinet Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Medinet Co (TSE:2370), the current Gross Margin % is 40.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinet Co (TSE:2370) Overvalued in 2026?
Based on GuruFocus' analysis, Medinet Co stock appears to be undervalued.
The current stock price of 円25.00 is trading 40.1% below its estimated GF Value™ of 円41.74.
GuruFocus considers Medinet Co to be Possible Value Trap.
Key valuation signals for TSE:2370:
Gross Margin %: 40.22% (35% above median its 10-year median of 29.76)
GF Value™: 円41.74 vs. price of 円25.00 (40.1% below fair value)
Industry Position: 34% below the Biotechnology median (#612 of 732)
No single metric tells the full story. See the TSE:2370 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinet Co Ltd is a Japan-based Contract Development and Manufacturing Organization (CDMO). The company is engaged in the research and development of regenerative medical products, investigational products, and specified cell products. MEDINET is a one-stop regenerative medicine and cell therapy solution provider. It provides value chain solutions including personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management solutions to medical institutions, research institutions, and biopharmaceutical companies.
41GF Score
Get the complete analysis for TSE:2370
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2370 has been successfully added to your 
